VIR vs. CYTK, GRFS, NUVL, VKTX, AXSM, TGTX, KRYS, OGN, RARE, and SRRK
Should you be buying Vir Biotechnology stock or one of its competitors? The main competitors of Vir Biotechnology include Cytokinetics (CYTK), Grifols (GRFS), Nuvalent (NUVL), Viking Therapeutics (VKTX), Axsome Therapeutics (AXSM), TG Therapeutics (TGTX), Krystal Biotech (KRYS), Organon & Co. (OGN), Ultragenyx Pharmaceutical (RARE), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry.
Vir Biotechnology vs.
Cytokinetics (NASDAQ:CYTK) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends, risk and profitability.
In the previous week, Vir Biotechnology had 6 more articles in the media than Cytokinetics. MarketBeat recorded 12 mentions for Vir Biotechnology and 6 mentions for Cytokinetics. Vir Biotechnology's average media sentiment score of 1.03 beat Cytokinetics' score of 0.43 indicating that Vir Biotechnology is being referred to more favorably in the news media.
Cytokinetics received 757 more outperform votes than Vir Biotechnology when rated by MarketBeat users. Likewise, 79.78% of users gave Cytokinetics an outperform vote while only 54.17% of users gave Vir Biotechnology an outperform vote.
Cytokinetics has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.
Cytokinetics has higher earnings, but lower revenue than Vir Biotechnology. Cytokinetics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.
65.3% of Vir Biotechnology shares are held by institutional investors. 3.4% of Cytokinetics shares are held by company insiders. Comparatively, 15.6% of Vir Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Vir Biotechnology has a net margin of -678.40% compared to Cytokinetics' net margin of -17,906.25%. Cytokinetics' return on equity of 0.00% beat Vir Biotechnology's return on equity.
Cytokinetics presently has a consensus target price of $83.64, indicating a potential upside of 82.87%. Vir Biotechnology has a consensus target price of $34.83, indicating a potential upside of 244.54%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than Cytokinetics.
Summary
Vir Biotechnology beats Cytokinetics on 11 of the 18 factors compared between the two stocks.
Get Vir Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vir Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:VIR) was last updated on 1/21/2025 by MarketBeat.com Staff
Free VIR Stock Alerts